CollPlant Biotechnologies (CLGN) EBT Margin (2017 - 2025)
CollPlant Biotechnologies (CLGN) reported EBT Margin of 5250.0% for Q4 2025, down 282683.0% on a YoY basis from N/an in Q4 2024, and down 15.27% quarter-over-quarter from 4554.55% in Q3 2025.
CollPlant Biotechnologies (CLGN) EBT Margin (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies has reported EBT Margin for 9 years, with the latest figure at 5250.0% in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin fell 282683.0% year-over-year to 5250.0%; the trailing twelve-month figure through Dec 2025 stood at 77.22% (down 11975.0% YoY), and the FY2025 full-year result was 468.28%, up 273812.0% from the prior year.
- EBT Margin for Q4 2025 stood at 5250.0%, down from 4554.55% in the prior quarter.
- The five-year high for EBT Margin was 138504.29% in Q3 2021, with the low at 113550.0% in Q3 2024.
- Historically, EBT Margin has averaged 7.45% across 5 years, with a median of 424.46% in 2021.
- Annual changes were most pronounced in 2021 — EBT Margin tumbled 53653752 bps — and 2025, when it jumped 10899545 bps.
- CollPlant Biotechnologies' EBT Margin stood at 1227.1% in 2021, then sank by 557 bps to 8062.07% in 2022, then surged by 79 bps to 1694.98% in 2023, then slumped by 43 bps to 2423.17% in 2024, then plunged by 117 bps to 5250.0% in 2025.
- The last three EBT Margin figures came in at 5250.0% (Q4 2025), 4554.55% (Q3 2025), and 1775.42% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | CollPlant Biotechnologies | 7.20 Mn | 7.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5,250.00% |
| Sep 30, 2025 | -4,554.55% |
| Jun 30, 2025 | 1,775.42% |
| Mar 31, 2025 | 80.19% |
| Dec 31, 2024 | -2,423.17% |
| Sep 30, 2024 | -113,550.00% |
| Jun 30, 2024 | 1,769.48% |
| Mar 31, 2024 | 4,417.35% |
| Dec 31, 2023 | -1,694.98% |
| Sep 30, 2023 | -0.01% |
| Jun 30, 2023 | 55.74% |
| Mar 31, 2023 | 812.70% |
| Dec 31, 2022 | -8,062.07% |
| Sep 30, 2022 | -4,099.08% |
| Jun 30, 2022 | -6,340.91% |
| Dec 31, 2021 | -1,227.10% |
| Sep 30, 2021 | 138,504.29% |
| Jun 30, 2021 | -424.46% |
| Mar 31, 2021 | 69.62% |
| Dec 31, 2020 | -222.30% |